SOURCE: NeuroInvestment

November 17, 2008 15:23 ET

Private CNS Company Review 2009 Released by NI Research

CARDIFF, CA--(Marketwire - November 17, 2008) - NI Research today announced the release of the 2009 edition of the Private CNS Company Review. The completely revised and updated 2009 edition provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities. Produced in pdf form for easy searchability, PCNS 2009 reviews 112 companies, many for the first time. It also provides lists of partnering opportunities at various developmental stages, and our first-ever discussion of the best M&A opportunities among these privately-held CNS firms.

149 pages. US$4000 (purchasers of CNS2008 Disorders/Therapeutics receives a 15% discount: $3400)

The topics and companies covered in PCNS 2009 are listed below. Please call or email us if you have any questions.

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and CNS Disorders/Therapeutics since 2007. NI Research also provides inlicensing consultation and custom services. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

PCNS 2009 Topics and Companies Covered:

Private Company Fates and Casualties  2003-8
Private CNS Company Licensing Opportunities
Top PCNS  Licensing Opportunities
Top PCNS  M&A Opportunities

Accera
AC Immune
Acumen  Pharmaceuticals
Adamas Pharmaceuticals
Affectis Pharmaceuticals
Affiris
Alzhyme
American Life Science Pharmaceuticals
Archer Pharmaceuticals
Argolyn Biosciences
Arcion Therapeutics
Ariston Pharmaceuticals
ArmaGen Technologies
AurimMed Pharma
Avera Pharmaceuticals
Axon-Neuroscience
Axxonis Pharma AG
Azevan Pharmaceuticals
Bayhill Therapeutics
BioArctic Neuroscience
Biocortech
BrainCells
BrainTact
Brane Discovery
Cambria Bioscience
Cara Therapeutics
Cellzome
CeNeRx BioPharma
Cenomed
Ceregene
Cervelo Pharma
Clera
Cognition Therapeutics
Cognosci
CoLucid
CoMentis
Conogenetix  Biosciences
D-Pharm
Embera Neurotherapeutics
ENKAM Pharmaceuticals
EnVivo Pharmaceuticals
Faust Pharmaceuticals
Galantos Pharma
Galenea
Gemac Pharma
GliaMed
Helicon Therapeutics
Intra-Cellular Therapies
KeyNeurotek
Kinexis
Knopp Neurosciences
Link Medicine
Maas Biolab
Mapreg
Marinus Pharmaceuticals
Medeia Therapeutics
MediProPharma
Mithridion
M's Science
Neuraxo Biotec
Neuraxon
Neuréva
Neurim
Neurimmune
Neurion
NeuroHealing
NeuroKos
Neuromed Pharmaceuticals
Neuronascent
Neuronautics
NeuroNova
NeuroProtect
NeuroTherapeutics Pharma
Neurotune AG
NoNO Inc.
NsGene
NuPathe
Ovation Pharmaceuticals
PainCeptor
PharmaNeuroBoost
Pharmaxon
Pharnext
Probiodrug
Proneuron Biotechnologies
Psyadon Pharmaceuticals
Reata Pharmaceuticals
RemeGenix
SanBio
Sanomune
Seaside Therapeutics
Senexis
Sierra Neuropharmaceuticals
Solace Pharmaceuticals
Solstice Neurosciences
Sonexa Therapeutics
Spinifex
Stealth Peptides
Synosia Therapeutics
TauRx
TheraQuest Biosciences
Thuris
Tikvah Therapeutics
Traxion Therapeutics
Trophos
Voyager Pharmaceuticals
Xenome Ltd
Xytis Pharmaceuticals
Yaupon Therapeutics
Zenobia
Zogenix

Programs by Company, Indication, Stage
Company Funding and VCs
VC Funding Roster

Contact Information